Education
About Us
Working with TipRanks
Follow Us
Regencell Bioscience Holdings Ltd. (RGC)
NASDAQ:RGC
Total Valuation
Regencell Bioscience has a market cap or net worth of $10.46B. The enterprise value is $1.65M.
Market Cap$10.46B
Enterprise Value$1.65M
Share Statistics
Regencell Bioscience has 494,488,920 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding494,488,920
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
Regencell Bioscience’s return on equity (ROE) is -0.74 and return on invested capital (ROIC) is -69.75%.
Return on Equity (ROE)-0.74
Return on Assets (ROA)-0.62
Return on Invested Capital (ROIC)-69.75%
Return on Capital Employed (ROCE)-0.74
Revenue Per Employee0.00
Profits Per Employee-298.68K
Employee Count12
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Regencell Bioscience is ―. Regencell Bioscience’s PEG ratio is 136.35.
PE Ratio―
PS Ratio0.00
PB Ratio1.73K
Price to Fair Value1.73K
Price to FCF-2.58K
Price to Operating Cash Flow-4.90K
PEG Ratio136.35
Income Statement
In the last 12 months, Regencell Bioscience had revenue of 0.00 and earned -3.58M in profits. Earnings per share was -0.01.
Revenue0.00
Gross Profit-392.74K
Operating Income-3.77M
Pretax Income-3.58M
Net Income-3.58M
EBITDA-3.19M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -2.00M and capital expenditures -2.69K, giving a free cash flow of -2.00M billion.
Operating Cash Flow-2.00M
Free Cash Flow-2.00M
Free Cash Flow per Share>-0.01
Dividends & Yields
Regencell Bioscience pays an annual dividend of $0.22, resulting in a dividend yield of ―
Dividend Per Share$0.22
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-3.19
52-Week Price Change16176.92%
50-Day Moving Average15.57
200-Day Moving Average13.29
Relative Strength Index (RSI)62.26
Average Volume (3m)233.90K
Important Dates
Regencell Bioscience upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Regencell Bioscience as a current ratio of 7.39, with Debt / Equity ratio of 11.20%
Current Ratio7.39
Quick Ratio7.39
Debt to Market Cap<0.01
Net Debt to EBITDA0.59
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Regencell Bioscience has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Regencell Bioscience EV to EBITDA ratio is -2.64K, with an EV/FCF ratio of -2.58K.
EV to Sales0.00
EV to EBITDA-2.64K
EV to Free Cash Flow-2.58K
EV to Operating Cash Flow-2.71K
Balance Sheet
Regencell Bioscience has $0.00 in cash and marketable securities with $0.00 in debt, giving a net cash position of $0.00 billion.
Cash & Marketable Securities$0.00
Total Debt$0.00
Net Cash$0.00
Net Cash Per Share$0.00
Tangible Book Value Per Share<$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Regencell Bioscience is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―